Sanofi’s Sale of $8 Billion Drugs Portfolio Said at a Standstill
This article is for subscribers only.
Sanofi’s plan to sell or find partners for an $7.9 billion portfolio of established drugs is at a standstill amid disagreements among top managers as to how to move forward, according to people familiar with the matter.
The assets have not been carved out into a separate business unit and management hasn’t decided what to keep or let go, the people said, asking not to be identified as the deliberations aren’t public. A transaction is unlikely to be agreed on soon, they said.